IDYA Revenue Breakdown
IDEAYA Biosciences, Inc. (IDYA). Quarter ended 2026-06-30 · 10-Q · every retained filed quarter remains available.
- 2025-12-31: Others Not split by product in the filing$218.71M100.00%; Total revenue $218.71M.
- 2024-12-31: Others Not split by product in the filing$7.00M100.00%; Total revenue $7.00M.
- 2023-12-31: Others Not split by product in the filing$23.39M100.00%; Total revenue $23.39M.
- 2022-12-31: Others Not split by product in the filing$50.93M100.00%; Total revenue $50.93M.
Revenue by product
Each year (12 month)
| Fiscal year end | Others | Total revenue |
|---|---|---|
| 2025-12-31 | Not split by product in the filing $218.71M 100.00% | $218.71M |
| 2024-12-31 | Not split by product in the filing $7.00M 100.00% | $7.00M |
| 2023-12-31 | Not split by product in the filing $23.39M 100.00% | $23.39M |
| 2022-12-31 | Not split by product in the filing $50.93M 100.00% | $50.93M |
| 2021-12-31 | Not split by product in the filing $27.94M 100.00% | $27.94M |
| 2020-12-31 | Not split by product in the filing $19.54M 100.00% | $19.54M |
| 2019-12-31 | $0.00 |
Each quarter (3 month)
| Quarter end | Others | Total revenue |
|---|---|---|
| 2026-06-30 | Not split by product $8.86M 100.00% | $8.86M |
| 2026-03-31 | Not split by product $6.56M 100.00% | $6.56M |
| 2025-12-31 | Not split by product $10.88M 100.00% | $10.88M |
| 2025-09-30 | Not split by product $207.83M 100.00% | $207.83M |
| 2024-12-31 | Not split by product $7.00M 100.00% | $7.00M |
| 2024-09-30 | Not split by product $0.00 | $0.00 |
| 2024-06-30 | Not split by product $0.00 | $0.00 |
| 2024-03-31 | Not split by product $0.00 | $0.00 |
| 2023-12-31 | Not split by product $3.92M 100.00% | $3.92M |
| 2023-09-30 | Not split by product $8.04M 100.00% | $8.04M |
| 2023-06-30 | Not split by product $3.54M 100.00% | $3.54M |
| 2023-03-31 | Not split by product $7.88M 100.00% | $7.88M |
| 2022-12-31 | Not split by product $4.02M 100.00% | $4.02M |
| 2022-09-30 | Not split by product $29.70M 100.00% | $29.70M |
| 2022-06-30 | Not split by product $5.85M 100.00% | $5.85M |
| 2022-03-31 | Not split by product $11.36M 100.00% | $11.36M |
| 2021-12-31 | Not split by product $2.96M 100.00% | $2.96M |
| 2021-09-30 | Not split by product $8.98M 100.00% | $8.98M |
| 2021-06-30 | Not split by product $8.76M 100.00% | $8.76M |
| 2021-03-31 | Not split by product $7.25M 100.00% | $7.25M |
| 2020-12-31 | Not split by product $10.57M 100.00% | $10.57M |
| 2020-09-30 | Not split by product $8.97M 100.00% | $8.97M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |